INSM vs. LEGN, ARNA, FTSV, CCXI, PTCT, TEVA, ALNY, GMAB, RPRX, and BMRN
Should you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Legend Biotech (LEGN), Arena Pharmaceuticals (ARNA), Forty Seven (FTSV), ChemoCentryx (CCXI), PTC Therapeutics (PTCT), Teva Pharmaceutical Industries (TEVA), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN).
Legend Biotech (NASDAQ:LEGN) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.
Legend Biotech presently has a consensus price target of $81.10, suggesting a potential upside of 102.70%. Insmed has a consensus price target of $56.38, suggesting a potential upside of 2.41%. Given Insmed's higher possible upside, equities research analysts clearly believe Legend Biotech is more favorable than Insmed.
In the previous week, Insmed had 61 more articles in the media than Legend Biotech. MarketBeat recorded 74 mentions for Insmed and 13 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.56 beat Insmed's score of 0.42 indicating that Insmed is being referred to more favorably in the news media.
Legend Biotech has a net margin of -135.92% compared to Legend Biotech's net margin of -236.74%. Legend Biotech's return on equity of 0.00% beat Insmed's return on equity.
70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 4.6% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Legend Biotech has higher earnings, but lower revenue than Insmed. Legend Biotech is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.
Insmed received 455 more outperform votes than Legend Biotech when rated by MarketBeat users. Likewise, 65.23% of users gave Insmed an outperform vote while only 64.89% of users gave Legend Biotech an outperform vote.
Legend Biotech has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.
Summary
Insmed beats Legend Biotech on 11 of the 17 factors compared between the two stocks.
Get Insmed News Delivered to You Automatically
Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
